Home/Sequel Med Tech/Dean Kamen

DK

Dean Kamen

Co-Founder

Sequel Med Tech

Therapeutic Areas

Diabetes Endocrinology

Sequel Med Tech Pipeline

Drug	Indication	Phase
twiist AID System	Type 1 Diabetes (insulin delivery)	Approved
Platform Expansion	Diabetes (Type 2) / Other Drug Delivery	Pre-clinical/Research

Leadership Team at Sequel Med Tech

Alan Lotvin, MD

CEO, Co-Founder, and Director

Vice President, US Sales

Head of People & Culture

Gabrielle Fernandes

Vice President, Financial Strategy and Investor Relations

View full Sequel Med Tech profile